11/07/2024 | Press release | Distributed by Public on 11/07/2024 12:01
AGEN1721, a First in Class FC Enhanced Bifunctional Antibody Target FAP and TGFB, Remodels the Tumor Microenvironment to Overcome Cancer Associated Fibroblast Mediated Immune[...]
